Effect of glucagon-like peptide-1 receptor agonists on circulating levels of leptin and resistin: A meta-analysis of randomized controlled trials

• Published in: Diabetes research and clinical practice Vol. 177; p. 108899
• Main Authors: Simental-Mendía, Luis E., Sánchez-García, Adriana, Linden-Torres, Enrique, Simental-Mendía, Mario
• Format: Journal Article
• Language: English
• Published: Elsevier B.V 01.07.2021
• Subjects: Glucagon-like peptide-1 receptor agonists; Leptin; Meta-analysis; Resistin; Glucagon-like peptide-1 receptor agonists; Leptin; Resistin; Meta-analysis
• ISSN: 0168-8227; 1872-8227
• DOI: 10.1016/j.diabres.2021.108899

•The effect of GLP-1 receptor agonists on leptin and resistin levels is inconclusive.•Results revealed that GLP-1 receptor agonists decrease leptin and resistin levels.•Further randomized controlled trials are needed to confirm our findings. Previous studies have found reduced concentrations of both leptin and resistin after glucagon-like peptide-1 receptor agonist (GLP-1 RA) treatment; however, the evidence in this field is inconclusive. Therefore, the aim of this meta-analysis of randomized controlled trials was to evaluate the effect of GLP-1 RA on both leptin and resistin levels. The present systematic review and meta-analysis included randomized controlled trials investigating the effect of GLP-1 RA on leptin and resistin concentrations. For this, PubMed-MEDLINE, Scopus, Web of Science, ClinicalTrials.gov, and Google Scholar databases were searched. A random-effects model and a sensitivity analysis were performed for meta-analysis. Meta-analysis of 13 randomized controlled trials comprising 1,025 subjects indicated that administration of GLP-1 RA significantly decreases leptin (WMD: −4.85 ng/mL, 95% CI: −9.32, −0.38, p = 0.03) and resistin (WMD: −1.40 ng/mL, 95% CI: −2.78, −0.01, p = 0.05) serum levels. However, the effect size was sensitive to four studies for both leptin and resistin concentrations. The results of this meta-analysis of randomized controlled trials suggest that GLP-1 RA therapy reduces both leptin and resistin levels.